255 related articles for article (PubMed ID: 37046255)
21. Immunosuppression therapy for idiopathic membranous nephropathy: systematic review with network meta-analysis.
Bose B; Chung EYM; Hong R; Strippoli GFM; Johnson DW; Yang WL; Badve SV; Palmer SC
J Nephrol; 2022 May; 35(4):1159-1170. PubMed ID: 35199314
[TBL] [Abstract][Full Text] [Related]
22. Cost effectiveness of implantable cardioverter defibrillators for 1.5 primary prevention of sudden cardiac arrest in China: an analysis from the Improve SCA study.
Sun H; Liu X; Fu J; Song Y; Qin X; Wang H
J Med Econ; 2024; 27(1):575-581. PubMed ID: 38566556
[TBL] [Abstract][Full Text] [Related]
23. Risk of infection with different immunosuppressive drugs combined with glucocorticoids for the treatment of idiopathic membranous nephropathy: A pairwise and network meta-analysis.
Liu D; Yang Y; Kuang F; Qing S; Hu B; Yu X
Int Immunopharmacol; 2019 May; 70():354-361. PubMed ID: 30852290
[TBL] [Abstract][Full Text] [Related]
24. Network meta-analysis and cost-effectiveness analysis of infliximab, cyclosporine and tacrolimus for ulcerative colitis.
Wang X; Li Q; Sun S; Liang X; Li H; Huang J; Zhao T; Hu J; Liu J; Hu Z; Duan Y; He J
Medicine (Baltimore); 2022 Dec; 101(51):e31850. PubMed ID: 36595876
[TBL] [Abstract][Full Text] [Related]
25. Single-dose Rituximab Therapy for Refractory Idiopathic Membranous Nephropathy: A Single-center Experience.
Katsuno T; Ozaki T; Kim H; Kato N; Suzuki Y; Akiyama S; Ishimoto T; Kosugi T; Tsuboi N; Ito Y; Maruyama S
Intern Med; 2017; 56(13):1679-1686. PubMed ID: 28674357
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness analysis of pembrolizumab in combination with chemotherapy compared with chemotherapy alone as first-line treatment for patients with advanced biliary tract cancer in China.
Zheng Z; Fang L; Cai H
BMC Cancer; 2023 Sep; 23(1):823. PubMed ID: 37667230
[TBL] [Abstract][Full Text] [Related]
27. The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche.
Main C; Pitt M; Moxham T; Stein K
Health Technol Assess; 2010 Oct; 14(Suppl. 2):27-32. PubMed ID: 21047488
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
Wu B; Chen H; Shen J; Ye M
Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of pembrolizumab for treatment of platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma in China: an economic analysis based on a randomised, open-label, phase III trial.
Xin W; Ding H; Fang Q; Zheng X; Tong Y; Xu G; Yang G
BMJ Open; 2020 Dec; 10(12):e038867. PubMed ID: 33371020
[TBL] [Abstract][Full Text] [Related]
30. Profile and primary treatment outcomes in membranous nephropathy.
Hemanth Kumar MK; Sandhu J; Sandhu JS
Saudi Med J; 2022 Sep; 43(9):1051-1056. PubMed ID: 36104046
[TBL] [Abstract][Full Text] [Related]
31. Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal.
Rojas-Rivera JE; Carriazo S; Ortiz A
Clin Kidney J; 2019 Oct; 12(5):629-638. PubMed ID: 31583088
[TBL] [Abstract][Full Text] [Related]
32. Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost-effectiveness analysis.
Zhang PF; Xie D; Wen F; Li Q
Cancer Med; 2020 Aug; 9(15):5312-5319. PubMed ID: 32489014
[TBL] [Abstract][Full Text] [Related]
33. Cost-Effectiveness Analysis of Anlotinib as Third- or Further-Line Treatment for Relapsed Small Cell Lung Cancer (SCLC) in China.
Gong J; Wan Q; Shang J; Qian X; Su D; Sun Z; Liu G
Adv Ther; 2021 Oct; 38(10):5116-5126. PubMed ID: 34417989
[TBL] [Abstract][Full Text] [Related]
34. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
[TBL] [Abstract][Full Text] [Related]
35. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
36. Cost-Effectiveness Analysis of Five Systemic Treatments for Unresectable Hepatocellular Carcinoma in China: An Economic Evaluation Based on Network Meta-Analysis.
Zhao M; Pan X; Yin Y; Hu H; Wei J; Bai Z; Tang W
Front Public Health; 2022; 10():869960. PubMed ID: 35493395
[TBL] [Abstract][Full Text] [Related]
37. Comparison of different therapies in high-risk patients with idiopathic membranous nephropathy.
Peng L; Wei SY; Li LT; He YX; Li B
J Formos Med Assoc; 2016 Jan; 115(1):11-8. PubMed ID: 26315481
[TBL] [Abstract][Full Text] [Related]
38. Cyclophosphamide induced early remission and was superior to rituximab in idiopathic membranous nephropathy patients with high anti-PLA2R antibody levels.
Xue C; Wang J; Pan J; Liang C; Zhou C; Wu J; Song S; Cui L; Zhang L; Liu Y; Dai B
BMC Nephrol; 2023 Sep; 24(1):280. PubMed ID: 37740193
[TBL] [Abstract][Full Text] [Related]
39. Cost-Effectiveness Analysis of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Venous Thromboembolism in China.
Sun KX; Cui B; Cao SS; Huang QX; Xia RY; Wang WJ; Wang JW; Yu F; Ding Y
Front Pharmacol; 2021; 12():716224. PubMed ID: 34744710
[No Abstract] [Full Text] [Related]
40. Cost-effectiveness analysis of adding transarterial chemoembolisation to lenvatinib as first-line treatment for advanced hepatocellular carcinoma in China.
Li W; Wan L
BMJ Open; 2023 Sep; 13(9):e074245. PubMed ID: 37751954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
